Fierce Biotech April 3, 2024
Medical app developer Click Therapeutics and its drugmaker partner Otsuka have secured an FDA clearance for what they describe as the first prescription digital program designed for adults with major depressive disorder (MDD) to be used alongside antidepressant therapies.
Rejoyn aims to further reduce MDD symptoms by complementing standard-of-care drug regimens, with a six-week digital treatment schedule that provides cognitive emotional training exercises and therapeutic lessons. The app also offers personalized reminders and messages to encourage adherence.
“Only a third of patients diagnosed with depression and who receive antidepressants as their first-line treatment, are successful,” Click co-founder and CEO David Benshoof Klein said in a statement. “These patients need new options that capitalize on proven-effective treatment strategies.”
Previously known as...
Today's Sponsors
Today's Sponsor